An observational study in Ocular Pain, OSDI and OPAS, sponsored by IRCCS Ospedale San Raffaele. Not yet recruiting. Per ClinicalTrials.gov, last updated 2024-10-24.
Sponsored by IRCCS Ospedale San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will be a single-center, observational, prospective validation study with survey and sample characteristics comparable to similar validation studies in the literature.
Pain represents a physiological response to the presence of tissue damage and is associated with numerous pathological conditions of the ocular surface.
Furthermore, in the presence of dysfunction of the nociceptive system, ocular pain can occur chronically with neuropathic features.
Pain quantification systems used to guide symptomatic therapy include the Ocular Surface Disease Index (OSDI); the Ocular Pain Assessment Survey (OPAS); and the Standardized Patient Evaluation of Eye Dryness (SPEED).
The OSDI assesses the presence of ocular symptoms, their impact on activities of daily living, and the presence of any aggravating factors. Although it is used in clinical practice and research activities in a translated version, it has never been validated in Italian.
The OPAS studies in more detail the characteristics of pain and associated symptoms and their impact on the patient's overall quality of life. This instrument has neither been translated nor validated in an Italian version.
The failure to validate the OSDI and OPAS questionnaires in the Italian version marks the starting point for this validative study.
The SPEED questionnaire, already translated and validated in Italian, will be used as the Gold Standard and will allow comparison of the other instruments.
Finally, six questions regarding imaginary scenarios of pain experiences will be proposed to assess the individual threshold of nociceptive sensitivity taken from the Pain Sensitivity Questionnaire (two for mild pain assessment, two for intermediate intensity stimuli, and two for intense pain situations).
Therefore, the primary objective of the study is to validate the Italian version of the OSDI and OPAS questionnaires while the secondary objective is to analyze the responses to the questionnaires by subgroups of general sensitivity to nociceptive stimuli.
31 studies on the registry are indexed under Eye Pain; 7 are open to participants now.
Browse Eye Pain studies →IRCCS Ospedale San Raffaele is the lead sponsor of 37 studies on the registry; 29 are open to participants now.
Counted across the registry records on this site, refreshed daily.
A cohort of patients with corneal and ocular surface diseases referred to the Ophthalmology O.U. - Cornea Center of IRCCS Ospedale San Raffaele will be studied.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The primary objective of the study is to validate the Italian version of the OSDI and OPAS questionnaires.
Time frame: The questionnaire will be acquired at day 0 (first time-point) and at day 7 (second time-point)
Secondary objective is the analysis of questionnaire responses by subgroups of general sensitivity to nociceptive stimuli.
Time frame: The questionnaire will be acquired at day 0 (first time-point) and at day 7 (second time-point)
No study locations are listed for this record.
Start is estimated for Nov 2024; primary completion for Nov 2025, 12 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
IRCCS Ospedale San Raffaele